IB
DNLI icon

Intrust Bank’s Denali Therapeutics DNLI Stock Holding History

Intrust Bank’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$424K Buy
16,477
+2,138
+15% +$43.9K 0.03% 298
2026
Q1 		$275K Buy
14,339
+3,175
+28% +$63.2K 0.02% 365
2025
Q4 		$184K Buy
11,164
+589
+6% +$9.94K 0.02% 388
2025
Q3 		$154K Buy
+10,575
New +$152K 0.01% 400

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Intrust Bank's DNLI Position: Q2 2026 in Review

Intrust Bank increased its Denali Therapeutics (DNLI) stake by 15% in Q2 2026, buying an estimated $43.9K and bringing the position to 16,477 shares worth $424K. The position accounts for 0.03% of the portfolio, ranked #298.

Intrust Bank first reported a position in DNLI in Q3 2025 and has held it in 4 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Intrust Bank held 16,477 shares of Denali Therapeutics worth $424K as of Q2 2026.
  • Intrust Bank bought 2,138 Denali Therapeutics shares in Q2 2026, an estimated $43.9K.
  • Denali Therapeutics made up 0.03% of Intrust Bank's portfolio in Q2 2026, its #298 holding.
  • Intrust Bank first reported a position in Denali Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Intrust Bank's 13F filing for Q2 2026, filed 5 Aug 2026.